ClinicalTrials.gg
CompletedNCT03996447PICTUREUpdated Sep 22, 2025Results posted

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

A Phase 3 interventional study of gadopiclenol and Gadobutrol 1Mmol/mL Solution for Injection Vial in CNS Lesion and Blood Brain Barrier Defect, sponsored by Guerbet. Completed at 33 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Read the detailed description

The purpose of this trial was to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol injection for Central Nervous System (CNS) lesion detection and visualization by conventional steady-state CNS imaging.

This is a multi-center, international, prospective, double-blind, randomized, controlled, cross-over with comparator trial in male and female patients presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) who are scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of the CNS.

This trial was conducted in 33 centers worldwide.

During the course of the trial, two MRIs were obtained from each patient: one unenhanced and gadopiclenol-enhanced MRI; and one unenhanced and gadobutrol-enhanced MRI. MRI evaluations were performed by on-site investigators and three independent off-site blinded readers.

02

Conditions studied

  • CNS Lesion
  • Blood Brain Barrier Defect
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which should have been performed within 12 months prior to ICF signature.

Exclusion criteria

Exclusion Criteria:

  • Patient presenting with acute or chronic renal insufficiency, defined as an estimated (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent injection
  • Patient presenting extra cranial lesions and/or extra-dural lesions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Other
    gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI

    cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI

    Drug: gadopiclenol · Drug: Gadobutrol 1Mmol/mL Solution for Injection Vial

  • Other
    gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI

    cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI

    Drug: gadopiclenol · Drug: Gadobutrol 1Mmol/mL Solution for Injection Vial

Interventions

  • single intravenous (IV) bolus injection at a rate of 2ml/second

  • DrugGadobutrol 1Mmol/mL Solution for Injection Vial

    single intravenous (IV) bolus injection at a rate of 2ml/second

06

What researchers measure

Primary outcomes

  1. Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI

    The lesion visualization (per patient) was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.

    Time frame: At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.

Secondary outcomes

  1. Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI

    The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.

    Time frame: At each of two MRI examinations with an interval of 2-14 days between 2 MRI examinations

07

Results

Posted Sep 22, 2025

Participant flow

First MRI Examination
Participant flow — First MRI Examination
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started128128
Completed125125
Not completed33
Withdrew: Adverse event20
Withdrew: Withdrawal by subject12
Withdrew: Protocol violation01
Washout
Participant flow — Washout
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started125125
Completed120122
Not completed53
Withdrew: Adverse event20
Withdrew: Follow-up unavailable due to covid-19 pandemic21
Withdrew: Withdrawal by subject01
Withdrew: Other reason11
Second MRI Examination
Participant flow — Second MRI Examination
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started120122
Completed120122
Not completed00

Outcome measures

PrimaryLesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI

The lesion visualization (per patient) was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.

Time frame:
At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI
mean of a score (on a scale) per patientPatients With Gadopiclenol Paired ImagesPatients With Gadopiclenol Pre Images
Border delineation - Reader 13.90 ± 0.022.08 ± 0.02
Border delineation - Reader 23.64 ± 0.041.74 ± 1.90
Border delineation - Reader 33.97 ± 0.032.61 ± 0.03
Internal morphology - Reader 13.92 ± 0.031.66 ± 0.03
Internal morphology - Reader 23.65 ± 0.031.88 ± 0.03
Internal morphology - Reader 33.97 ± 0.042.01 ± 0.04
Contrast enhancement - Reader 13.77 ± 0.031.00 ± 0.03
Contrast enhancement - Reader 23.58 ± 0.031.00 ± 0.03
Contrast enhancement - Reader 33.90 ± 0.021.00 ± 0.02
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.82 · 95% CI 1.76 to 1.88
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.90 · 95% CI 1.81 to 2.00
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.36 · 95% CI 1.29 to 1.44
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.26 · 95% CI 2.20 to 2.33
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.77 · 95% CI 1.69 to 1.85
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.96 · 95% CI 1.85 to 2.06
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.77 · 95% CI 2.69 to 2.85
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.58 · 95% CI 2.49 to 2.67
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.90 · 95% CI 2.84 to 2.95
SecondaryLesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI

The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.

Time frame:
At each of two MRI examinations with an interval of 2-14 days between 2 MRI examinations
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI
mean of a score (on a scale) per patientPatients With Gadopiclenol Paired ImagesPatients With Gadobutrol Paired Images
Border delineation - Reader 13.91 ± 0.023.93 ± 0.02
Border delineation - Reader 23.64 ± 0.043.60 ± 0.04
Border delineation - Reader 33.97 ± 0.013.95 ± 0.01
Internal morphology - Reader 13.93 ± 0.023.93 ± 0.02
Internal morphology - Reader 23.64 ± 0.043.62 ± 0.04
Internal morphology - Reader 33.97 ± 0.023.92 ± 0.02
Contrast enhancement - Reader 13.78 ± 0.043.77 ± 0.04
Contrast enhancement - Reader 23.57 ± 0.043.52 ± 0.04
Contrast enhancement - Reader 33.89 ± 0.033.81 ± 0.03
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 (The Null hypothesis was rejected if the 2-sided 95% Confidence Interval (CI) for the difference \[gadopiclenol scores mean - gadobutrol scores mean\] had its lower limit above -0.35.) · Mean difference (final values): -0.02 · 95% CI -0.06 to 0.02The Student's t-based 95% CIs of the difference between gadopiclenol and gadobutrol were constructed for each of 3 co-primary criteria.
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 (The Null hypothesis was rejected if the 2-sided 95% Confidence Interval (CI) for the difference \[gadopiclenol scores mean - gadobutrol scores mean\] had its lower limit above -0.35.) · Mean difference (final values): 0.03 · 95% CI -0.04 to 0.11The Student's t-based 95% CIs of the difference between gadopiclenol and gadobutrol were constructed for each of 3 co-primary criteria.
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.02 · 95% CI -0.01 to 0.05
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -0.01 · 95% CI -0.04 to 0.03
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.02 · 95% CI -0.05 to 0.09
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.05 · 95% CI 0.01 to 0.08
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = 0.0001 · Mean difference (final values): 0.01 · 95% CI -0.04 to 0.07
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.05 · 95% CI -0.03 to 0.12
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.09 · 95% CI 0.03 to 0.15

Adverse events

Collected over Adverse events were recorded from informed consent signature up to one day after the second MRI (i.e., minimum of 4 days and a maximum of 23 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gadopiclenol0/247 (0%)0/247 (0%)36/247 (14.6%)
Gadobutrol1/245 (0.4%)1/245 (0.4%)42/245 (17.1%)
Most frequent serious events
Most frequent serious events
EventGadopiclenolGadobutrol
General Physical Health DeteriorationGeneral disorders0/2471/245
Most frequent other events
Showing 10 of 47
Most frequent other events
EventGadopiclenolGadobutrol
Injection site painGeneral disorders5/2475/245
HeadacheNervous system disorders2/2475/245
Blood creatinine increasedInvestigations1/2475/245
DizzinessNervous system disorders5/2471/245
NauseaGastrointestinal disorders4/2471/245
Injection site bruisingGeneral disorders3/2473/245
Injection site erythemaGeneral disorders1/2473/245
Injection site warmthGeneral disorders1/2472/245
Injection site haemorrhageGeneral disorders0/2472/245
Vessel puncture site haemorrhageGeneral disorders0/2472/245

Baseline characteristics

The analysis was based on participants. For the primary analysis to demonstrate the superiority of gadopiclenol-enhanced MRI compared to unenhanced MRI, the analysis population was patients who had both Pre (unenhanced) and Paired (combined unenhanced and contrast-enhanced) images with gadopiclenol assessable for primary criteria for at least one matching lesion for at least one off-site reader: 119 patients of Arm 1 who performed first MRI and 120 patients of Arm 2 who performed second MRI.

Age, Continuous
Age, Continuous(years)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Mean58.4 ± 13.456.1 ± 14.257.2 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Female6163124
Male5857115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Hispanic or Latino61117
Not Hispanic or Latino113109222
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
American Indian or Alaska Native51116
Asian10818
Native Hawaiian or Other Pacific Islander011
Black or African American224
White10198199
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
South Korea7512
Belgium202
Hungary5743100
United States172441
Taiwan224
Poland111627
Italy101222
Mexico51116
France246
Germany123
Spain516
Weight
Weight(Kg)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Mean77.9 ± 19.578.4 ± 20.878.1 ± 20.1
08

Study locations

33 sites
  • ASCLEPES Research Centers
    Panorama City, California 91402, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Northwest Neurology, Ltd.
    Rolling Meadows, Illinois 600008, United States
  • University of Missouri Hospital and Clinic
    Columbia, Missouri 65212, United States
  • University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • South Carolina Clinical & Translational Research (SCTR) Institute
    Charleston, South Carolina 29425, United States
  • University Of Washington - Medical Center
    Seattle, Washington 98195, United States
  • ZNA Middelheim
    Antwerp, Belgium
  • UZ Brussel - Campus Jette
    Brussels, 1090, Belgium
  • CHRU - Hôpital Roger Salengro - Neurologie
    Lille, France
  • Centre Hospitalier Sainte-Anne
    Paris, 75014, France
  • CHU La Miletrie
    Poitiers, France
  • CHRU Strasbourg Hôpital de Hautepierre
    Strasbourg, 67098, France
  • Uniklinik Mannheim
    Mannheim, 68167, Germany
  • Semmelweis Egyetem - Neurology
    Budapest, 1083, Hungary
  • Orszagos Klinikai Idegtudomanyi Intezet
    Budapest, 1145, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont - Idegsebeszeti Klinika
    Pécs, Pécs, Hungary
  • Szegedi Tudomanyegyetem AOK
    Szeged, 6725, Hungary
  • ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila, Ospedale Regionale San Salvatore
    L’Aquila, Italy
  • Fondazione I.R.C.C.S. C.Mondino
    Pavia, 27100, Italy
  • Istituto Neurologico Mediterraneo-Neuromed, I.R.C.C.S.
    Pozzilli, 86077, Italy
  • Azienda Sanitaria Universitaria Integrata di Trieste-PO Cattinara
    Trieste, 34149, Italy
  • Axis Heilsa S. de R.L. de C.V. (Althian)
    Monterrey, 64060, Mexico
  • Clinical Research Institute S.C
    Tlalnepantla, 54055, Mexico
  • Uniwersyteckie Centrum Kliniczne w Gdańsku, Zakład Radiologii
    Gdansk, 80-214, Poland
  • Konkuk University Medical Center
    Seoul, 05030, South Korea
  • Asan Medical Center
    Seoul, 5505, South Korea
  • Hospital del Mar
    Barcelona, 08003, Spain
  • M.D. Anderson Cancer Center Madrid
    Madrid, 28033, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Loevner LA, Kolumban B, Hutoczki G, Dziadziuszko K, Bereczki D, Bago A, Pichiecchio A. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol. 2023 May 1;58(5):307-313. doi: 10.1097/RLI.0000000000000944. Epub 2022 Dec 19. PubMed 36729404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Sep 2020, 15 months.

Results were first posted in Sep 2025, 5 years after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2019
First posted
Jun 24, 2019
StartActual
Jun 3, 2019
Primary completionActual
Sep 11, 2020
CompletionActual
Sep 11, 2020
Results delay requested
May 12, 2021
Results first posted
Sep 22, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03996447
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Jun 3, 2019
Primary completion
Sep 11, 2020
Completion
Sep 11, 2020
Results posted
Sep 22, 2025
Last update
Sep 22, 2025

Study contacts

Lorie Loevner, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion